Source: Annual Congress 2006 - Treatment and complications of treatment of lung cancer and malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. Stehle, A. Groeschel, G. W. Sybrecht (Homburg/Saar, Germany). Response to targeted therapy in a 68-year-old male smoker with a squamous cell lung cancer treated with an epidermal growth factor receptor antagonist. Eur Respir J 2006; 28: Suppl. 50, 4319

Member's Comments

No comment yet.

Related content which might interest you: Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 183-193 Year: 2011 Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 Expression of alpha and beta estrogen, and progesterone receptors in adenocarcinoma and squamous lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Stage IV adenocarcinoma of the lung with classical epidermal growth factor receptor mutation and a thought-provoking course Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Source: Eur Respir J 2005; 25: 329-335 Year: 2005 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009